Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies

The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The activity of cetuximab was compared with that of commonly used treatments in this setting.

[1]  M. Goldwasser,et al.  Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Moroni,et al.  Second-Line Chemotherapy with Bleomycin, Methotrexate, and Vinorelbine (BMV) for Patients with Squamous Cell Carcinoma of the Head, Neck and Esophagus (SCC-HN&E) Pretreated with a Cisplatin-Containing Regimen: A Phase II Study , 2003, Journal of chemotherapy.

[3]  R. Day,et al.  Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .

[4]  M. Merlano,et al.  Second-line treatment with docetaxel after failure of a platinum-based chemotherapyin squamous-cell head andneck cancer , 2002 .

[5]  J. Baselga,et al.  Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Saltz,et al.  The presence and intensity of the cetuximab- induced acne-like rash predicts increased survival in studies across multiple malignances , 2003 .

[7]  R H Wheeler,et al.  Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[9]  D. Bigner,et al.  Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha. , 1998, Journal of the National Cancer Institute.

[10]  A. Schueler,et al.  Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Hutchins,et al.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Burtness,et al.  Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Carlos Arteaga,et al.  Targeting HER1/EGFR: a molecular approach to cancer therapy. , 2003, Seminars in oncology.

[14]  J. Mendelsohn,et al.  Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. , 1994, The Journal of biological chemistry.

[15]  E. Van Cutsem,et al.  Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[17]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[18]  M. Merlano,et al.  Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[20]  J. Bourhis,et al.  Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Goldstein,et al.  Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  A. Carvalho,et al.  Natural history of untreated head and neck cancer. , 2000, European journal of cancer.

[23]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[24]  A. Iop,et al.  Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  G. N. Hansen,et al.  Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas , 2004, European Archives of Oto-Rhino-Laryngology.

[26]  A. Schueler,et al.  Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies , 2005 .

[27]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[28]  R. Rosso,et al.  Failure of Second-Line Therapy to Modify Survival in Relapsed Squamous Cell Carcinoma of the Head and Neck , 1985, Tumori.

[29]  J. Mendelsohn,et al.  Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. , 1993, Cancer research.

[30]  N. Hanna.  Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy , 2008 .

[31]  W. Hong,et al.  Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Restivo,et al.  Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck. , 1994, ORL; journal for oto-rhino-laryngology and its related specialties.

[33]  Roy S Herbst,et al.  Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. , 2002, Seminars in oncology.

[34]  J. Baselga,et al.  Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Mendelsohn.  Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  E. Van Cutsem,et al.  The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies , 2005, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[37]  C. Arteaga,et al.  The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. , 2003, Seminars in oncology.

[38]  H. Iro,et al.  Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients , 1998, Cancer.

[39]  N. Keldsen.  Cisplatin as second line chemotherapy in advanced or recurrent squamous cell carcinoma of head and neck region. , 1987, Acta oncologica.

[40]  R. Stupp,et al.  A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).